PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2011 February 1.
Published in final edited form as:
PMCID: PMC2820129
NIHMSID: NIHMS164213

Nonsteroidal anti-inflammatory drugs and risk of ovarian and endometrial cancers in the Iowa Women’s Health Study

Abstract

Background

Several epidemiological studies have shown inverse associations between use of nonsteroidal anti-inflammatory drugs (NSAIDs) and incident ovarian cancer but the results are inconsistent. There have been only a few studies examining possible links between NSAIDs and endometrial cancer risk. We investigated associations between use of NSAIDs and incident ovarian and endometrial cancers in a prospective cohort of about 20,000 women aged 58 to 76 years in 1992. Participants were asked how often they used aspirin and non-aspirin NSAIDs. Over 15 years, 311 endometrial and 167 ovarian incident malignancies were identified. Multivariate-adjusted hazard ratios (HR) were estimated using Cox proportional regression.

Results

Compared to women who reported no use of aspirin, the relative risks of ovarian cancer for those who used aspirin less than 2, 2–5 times, and 6 or more times per week were 0.83, 0.77 and 0.61, respectively (p-trend=0.04). We did not observe any association between non-aspirin NSAIDs use and ovarian cancer risk. Neither did we find associations between aspirin or non-aspirin NSAIDs use and risk of endometrial cancer.

Conclusions

Our results suggest a possible inverse association between frequency of aspirin use and risk of ovarian cancer.

Keywords: ovarian cancer, endometrial cancer, non-steroidal anti-inflammatory drugs, prospective study

Introduction

Chronic inflammation is implicated in cancer etiology and progression (13). Chronic inflammation is characterized by production of cyclo-oxygenase (COX) and prostaglandins, generation of reactive oxygen species, and secretion of inflammatory cytokines, which may induce rapid cell division, DNA damage and mutations, and tumor growth (4).

Evidence for an association between inflammation and carcinogenesis is strongest for colorectal cancer, but relationships with inflammation have been also shown for malignancies of the pancreas, kidney, bladder, stomach, and ovaries (1). The following evidence supports the hypothesis that inflammation increases ovarian cancer risk: exposure to talc and endometriosis are associated with inflammation and increased ovarian cancer risk (5, 6); increased C-reactive protein – a biologic marker of chronic systemic inflammation – has been shown to be associated with increased ovarian cancer risk (7); and in vitro studies demonstrated that non-steroidal anti-inflammatory drugs (NSAIDs), both aspirin and non-aspirin types, may potentially inhibit the tumor growth and induce apoptosis of ovarian cancer cell lines (810). Several epidemiological studies (at least 10 case-control and 3 cohort studies) examined associations between NSAIDs and ovarian cancer risk, but their results were not consistent (1125). In a review of the risk factors for ovarian cancer, Hankinson et al [2006] concluded that there is a moderate inverse association between ovarian cancer and analgesic use; but data are limited and more large epidemiologic studies are needed (5).

There is also laboratory evidence that aspirin and non-aspirin NSAIDs suppress proliferation and induce apoptosis of endometrial cancer cell lines in a dose-dependent manner (2628). However, none of the three published epidemiological studies found associations between any NSAIDs and endometrial cancer overall (2931). Yet, a significant risk reduction for NSAIDs was observed among non HRT users in one of these studies (31) and among obese women in two of the studies (30,31). It is important to better understand the potential chemopreventive effects of NSAIDs for the two most common gynecological cancers – ovarian and endometrial cancers. Our goal was to evaluate the association between self-reported frequency of aspirin and non-aspirin NSAIDs use and incidence of these cancers among elderly women in the Iowa Women’s Health Study (IWHS), a large prospective cohort study.

Materials and Methods

Detailed descriptions of the IWHS cohort have been published previously (3234). In brief, IWHS was initiated in 1986 when a baseline questionnaire was mailed to 98,030 women aged 55 to 69 years, randomly selected from the Iowa driver’s license list. The 41,836 women who completed the questionnaire (42.7%) constituted the cohort.

Five follow-up questionnaires were mailed to cohort subjects to update vital status, residence, and exposure information; the response rates were 91% in 1987, 90% in 1989, 83% in 1992, 79% in 1997, and 70% in 2004. Data from follow-up surveys indicated that the migration rate from Iowa among cohort members is <1% annually, allowing nearly complete follow-up for cancer incidence end points (35). The vital status of all non-responders to follow-up questionnaires was identified by linkage with the National Death Index.

The current use of aspirin and non-aspirin NSAIDs in the cohort was ascertained on the 1992 questionnaire. Respondents were asked: “How often do you take aspirin? Examples of aspirin included Bufferin, Anacin, enteric-coated aspirin, Ecotrin, and Excedrin: never, less than one per week, one per week, 2 – 5 per week, and 6+ per week.” Use of non-aspirin NSAIDs was assessed by asking: “How often do you take other nonsteroidal anti-inflammatory drugs or arthritis medicines? Examples included Ibuprofen, Advil, Nuprin, Motrin, Naprosyn, Feldene, and Clinoril: never, less than one per week, one per week, 2 – 5 per week, and 6+ per week.” Respondents were instructed to exclude acetaminophen and Tylenol use in both questions. Data on dose and duration were not available.

The baseline questionnaire asked standard information about lifestyle behaviors and sociodemographic factors, medical histories, and anthropometric factors. The participants reported their current weight and height, and their hip and waist circumferences measured by a friend, using a paper tape measure provided with the questionnaire. Detailed information about their reproductive history was collected: age at menarche, age at menopause and the reason for it, details of each pregnancy (up to 10), and whether or not they had had their uterus and/or one or both ovaries surgically removed (updated in 1992). In addition, they were asked about their family history of cancer, the history of endometriosis, history of oral contraceptive use and duration, and history of hormone replacement therapy (HRT). Information about weight, alcohol intake and smoking status was updated in 1992, and questions about heart disease, diabetes, hypertension, and HRT use were asked at each follow up. The 1992 survey also queried whether participants had been diagnosed with migraines, rheumatoid arthritis and osteoarthritis. Data about hysterectomy and oophorectomy status were collected at a third time in 2004.

Ovarian and endometrial cancer cases were ascertained through the State Health Registry of Iowa, part of the National Cancer Institute’s Surveillance, Epidemiology, and End Results Program (SEER), via an annual computer match of name, maiden name, date of birth, address, and social security number. Primary site, morphology, extent of disease, and date of diagnosis were obtained for each incident cancer case from 1992 through 2006. Only cases diagnosed within the state of Iowa were captured.

We firstly excluded participants if they did not complete 1992 survey (n=8,819), then if they had cancer at baseline or were diagnosed with cancer other than skin cancer before 1992 (n=4,439), and if they did not complete both questions about NSAIDs (n=540). In addition, women with full oophorectomy and unknown oophorectomy status were excluded for ovarian cancer analysis (n=6,338), and women with hysterectomy and unknown hysterectomy status were excluded for endometrial cancer analysis (n=10,328). Among ovarian cancer cases, non-epithelial cancer cases were excluded (n=6); and among endometrial cancer cases, endometrial sarcomas and Muellerian mixed tumors (n=13) were excluded.

As a result, 21,694 women were available for the ovarian cancer analysis, with 157 epithelial ovarian cancers detected over 15 years of follow-up. For the endometrial cancer analysis, the cohort consisted of 17,697 women and 311 endometrial cancers.

Person-years of follow-up for endometrial and ovarian cancer cases were calculated as the time between 1992 to endometrial or ovarian cancer, respectively. All other participants were followed up to the date of death, the estimated date of emigration from Iowa (assigned as midpoint between the last completed questionnaire in Iowa and the next follow-up questionnaire completed elsewhere or non-Iowa death), or December 31, 2006, whichever occurred first.

We used SAS (SAS Institute Inc., Cary, NC) for analysis. Chi-square tests were performed to determine whether or not characteristics differed according to frequency of aspirin and non-aspirin NSAIDs use. Age-adjusted and multivariate-adjusted hazard ratios (HR) of ovarian and endometrial cancers and their 95% confidence intervals (CIs) were computed by proportional hazards regression (program PHREG) separately for aspirin and non-aspirin NSAIDs. For each exposure, women who reported using NSAIDs less than or equal to one time per week were combined into one group, resulting in categories of never (reference), less than 2 times per week, 2 – 5 times per week, and 6+ times per week.

Potential covariates in a multivariate-adjusted model were tested if they were associated with ovarian or endometrial cancer (depending on the analysis) or NSAIDs use in this analysis. The final model for ovarian cancer included age, body mass index (BMI) (continuous), history of HRT use (yes/no), number of live births (0, 1–2, 3–4, >4), history of heart disease (yes/no), and partial oophorectomy (yes/no). Alcohol, physical activity, smoking status and pack-years of smoking, education, waist-to-hip ratio, age at menopause, and age at menarche, endometriosis, hysterectomy status, family history of breast and/or ovarian cancer were not associated with ovarian cancer in this analysis and were not included. In addition, we adjusted for personal history of migraines and history of either rheumatoid arthritis or osteoarthritis. Since they did not markedly change the estimates, they were not included in the final model. In order to minimize potential confounding by indication, we also examined associations after excluding women who had reported heart disease, arthritis and migraines.

The final model for endometrial cancer included age, BMI (less than 25, 25–29.9 and ≥30 kg/m2), alcohol use (never/ever), age at menopause (≤44, 45–49, 50–54, ≥ 55 years), age at menarche (≤11, 12, 13, ≥14 years), history of oral contraceptive and HRT use (yes/no), history of diabetes and hypertension (yes/no). Physical activity, education, smoking status and pack-years, number of live births, age at first live birth, and family history of uterine cancer were not associated with endometrial cancer and were not included. In order to compare our results with Moysich et al [2005] and Viswanathan et al [2008] (30, 31), who reported associations between NSAIDs and endometrial cancer for obese women, and Viswanathan et al [2008] who observed an association for never users of HRT (31), the analysis was repeated after stratifying by BMI categories (normal, <25 kg/m2; overweight, 25–29.9 kg/m2; and obese, ≥30 kg/m2) and HRT use (yes/no).

We also repeated analyses after excluding ovarian or endometrial cancer cases (depending on the analysis) diagnosed within two and three years after start of follow-up to exclude women who may have used NSAIDs more frequently to treat symptoms of preclinical cancer. In addition, we stratified the time of follow-up approximately at midpoint (1992–1999 and 2000–2006) and compared hazard risk of ovarian or endometrial cancer in relation to NSAIDs use in each period. Because we did not know the dates of oophorectomy and hysterectomy during the follow-up, we were not able to censor participants at the time of their surgery. So, we conducted a sensitivity analysis among respondents to 2004 surveys to allow us to exclude women who reported a bilateral oophorectomy or hysterectomy in 2004 in the analysis of ovarian or endometrial cancer, respectively. Although the power was decreased, all associations were similar before and after exclusions. In our primary analysis, all women at risk in 1992 were included.

The IWHS was approved by the University of Minnesota’s Institutional Review Board and return of the questionnaire was considered informed consent.

Results

The mean age of women at risk for ovarian cancer and for endometrial cancer was 67.5 years (range 58–76 y) in 1992. Among women at risk for ovarian cancer, 72.0% ever used aspirin, 38.5% ever used non-aspirin NSAIDs, 28.1% used both, and 17.7% did not use any NSAIDs. Among aspirin users and non-users, 37.1% and 39.1% ever used non-aspirin NSAIDs, respectively. The percentages were very similar in the cohort at risk for endometrial cancer, but the fraction of non-aspirin NSAIDs use (37.1%) was slightly smaller. Because the patterns of distribution of characteristics across aspirin and non-aspirin NSAIDs were similar among participants at risk for ovarian and endometrial cancers, the prevalence of characteristics is presented for those at risk for ovarian cancer (Table 1).

Table 1
Mean age (y) and prevalence of participant characteristics (%) by frequency of aspirin or non-aspirin NSAIDs use, IWHS 1992–2006.

Frequent users of aspirin and non-aspirin NSAIDs were more likely to report history of arthritis (rheumatoid arthritis and/or osteoarthritis), migraines, and cardiovascular disease. Women using non-aspirin NSAIDs more frequently were more likely to be obese, have history of oral contraceptive and HRT use, have had a hysterectomy, and were somewhat more likely to report endometriosis. These associations were less pronounced for aspirin users. Other risk factors for ovarian or endometrial cancer such as number of live births, age at first live birth, age at menopause and menarche, nulliparity, family history of breast, ovarian, and uterine cancers, education, alcohol, and smoking were not associated with frequency of aspirin or non-aspirin NSAIDs use.

In an age-adjusted model, there was an indication of an inverse association between frequency of aspirin use and incident ovarian cancer (Table 2). After further adjustment for covariates, the trend became slightly stronger and statistically significant. Compared with aspirin non-users, the hazard ratio of ovarian cancer for women who reported using aspirin less than 2 times per week, 2 – 5 times per week, or 6+ times per week were 0.83 (95% CI, 0.56;1.22), 0.77 (95% CI, 0.48;1.24), and 0.61 (95% CI, 0.37;0.99), respectively (p-trend=0.04). Adjustment for non-aspirin NSAIDs use did not noticeably change the relationship between aspirin use and ovarian cancer. After restricting analysis to the women without heart disease, the HR for ever users of aspirin versus no use was 0.69 (95% CI, 0.48;0.99) and a dose-dependent relationship persisted (not shown here). Inverse dose-dependent relationships (not shown here) held among those who did not have a history of any arthritis and among those without a history of migraines.

Table 2
Age and multivariate-adjusted* hazard ratios (HRs) for ovarian cancer in relation to the use of aspirin and non-aspirin NSAIDs, IWHS 1992–2006.

The inverse relationships remained after exclusion of cases diagnosed during the first two and three years of follow-up. In addition, results stratified by follow-up period i.e., 1992–1999 and 1999–2006 were similar to each other and to the overall period of study (data not shown).

Contrary to use of aspirin, use of non-aspirin NSAIDs (Table 2) was not associated with ovarian cancer incidence. The multivariate-adjusted hazard ratios were 0.65, 1.08, and 1.12 for women who used non-aspirin NSAIDs less than 2, 2 – 5 times, and 6+ times per week compared to non-users of non-aspirin NSAIDs (p=0.27). These results were not substantively changed when adjusted for aspirin use.

Compared with never use of either aspirin or non-aspirin NSAIDs, use of both medications was inversely associated with ovarian cancer incidence (multivariate HR=0.65 (95% CI, 0.40;1.07)). There was no evidence for an interaction between use of aspirin and non-aspirin NSAIDs (p=0.39), but power for this analysis was small.

Table 3 shows the relationship between incident endometrial cancer and frequency of aspirin and non-aspirin NSAIDs use. Compared with non-users of aspirin, the multivariate-adjusted HRs for women who reported use of aspirin less than 2 times, 2 – 5 times, and 6+ weekly were 0.78 (95% CI, 0.58;1.04), 0.89 (95% CI, 0.63;1.25), and 0.85 (95% CI, 0.61;1.18), respectively (p-trend=0.50). After stratification by BMI categories or history of HRT use, there were still no patterns of relationships between aspirin use and endometrial cancer risk in any of the categories (data not shown).

Table 3
Age- and multivariate-adjusted* hazard ratios (HRs) for endometrial cancer in relation to the use of aspirin and non-aspirin NSAIDs, IWHS 1992–2006.

When use of non-aspirin NSAIDs and incident endometrial cancer were examined, the multivariate HRs (use versus no use) were 0.86 (95% CI, 0.63;1.18), 1.16 (95% CI, 0.78;1.72), and 0.85 (95% CI, 0.58;1.22) for those who reported use of NSAIDs less than 2, 2 – 5, and 6+ times weekly, respectively (p-trend=0.73) (Table 3).

Discussion

In this prospective cohort of elderly women there was an inverse association between frequency of aspirin use and ovarian cancer risk. Adjustment for the use of non-aspirin NSAIDs did not substantively change these results. The findings were similar when we excluded women diagnosed with ovarian cancer during the first two and three years of follow-up.

There was no association between frequency of non-aspirin NSAIDs use and ovarian cancer risk. For endometrial cancer, we observed no associations between frequency of any NSAIDs and endometrial cancer risk, even after stratification by BMI categories and use of HRT.

Our null findings for NSAIDs use and endometrial cancer, overall, are in agreement with previous findings from 1 case-control (30) and 2 cohort studies (29, 31). However, Moysich et al [2005] and Viswanathan et al [2008] reported inverse associations among obese women (30, 31), and Viswanathan et al [2008] also observed an inverse association among never users of HRT (31). These two studies suggested that in obese women NSAIDs decrease production of COX-2 and inflammatory cytokines and reduce estrogen exposure in endometrial tissue through decreased aromatase expression (30, 31). We did not observe associations among never users of HRT or obese women; the latter being consistent with null findings among obese women in the NIH-AARP Diet and Health Study (29). Of note, findings from epidemiological studies of NSAIDs use and endometrial cancer are not consistent with in vitro studies. Laboratory experiments have found that both aspirin and non-aspirin NSAIDs inhibit human endometrial cancer cells in a time and dose-dependent manner through COX-2 dependent and COX-2 independent mechanisms (2628). There could be several explanations for the discrepancy between epidemiological and in vitro studies: 1) NSAIDs may inhibit progression rather than induction of endometrial cancer, 2) use of NSAIDs is irregular in epidemiological studies and their dosage is much smaller than in in vitro studies (19), or measurement error in epidemiological studies could mask a small effect.

More than ten epidemiological studies and three meta-analyses investigated associations between NSAIDs use and incident ovarian cancer (1125, 3639). Findings from all the meta-analyses for incident ovarian cancer in relation to aspirin use were similar (3638). For example, the meta-analysis by Bosetti et al [2006] presented pooled results from 6 case-control and 2 cohort studies (37). In the analysis of case-control studies, the pooled RR was 0.82 (95% CI, 0.69;0.99) for aspirin users versus non users. No association of aspirin with ovarian cancer was reported in the pooled analysis of the two cohort studies; overall, the pooled RR for aspirin users was 0.89 (95% CI, 0.78;1.02) compared to non users of aspirin.

A randomized controlled trial, the Women’s Health Study, designed to study cardiovascular disease endpoints, reported that the RR of ovarian cancer was 0.95 (95% CI, 0.68, 1.35) in relation to aspirin use (39). However, the dosage of aspirin assigned to the treatment group was small – 100 mg every other day for ten years, and could be insufficient for prevention of cancer. It is noteworthy that the same trial reported no protective effect of low-dose aspirin on colorectal cancer incidence, whereas most observational studies, which assessed higher aspirin dosage (including IWHS cohort study), found inverse associations (37, 40).

Recently, five more studies have been published on associations between NSAIDs use and ovarian cancer risk and the results are inconsistent. Two case-control studies observed inverse associations of ovarian cancer risk with NSAIDs use overall and with aspirin (all RRs were about 0.7) (21, 25), whereas two other case-control studies reported no inverse relationships (14, 17). An updated analysis in a large cohort study, Nurses’ Health Study (NHS) and Nurses’ Health Study II (NHS-II) (19), used a longer follow-up and a larger number of cases than their study in 2002 (13) that was included in the meta-analyses cited above (37). Their data again showed no overall association between aspirin and ovarian cancer risk (19). However, there was an indication of an inverse association between non-aspirin NSAIDs use and ovarian cancer risk and between any NSAIDs use and risk of borderline ovarian tumors.

Thus, our finding of an inverse association between aspirin and ovarian cancer risk are in agreement with findings from the majority of case-control studies but not consistent with findings from the NHS-NHS-2 cohorts (19). A potential explanation is that our study population is different from those in these cohorts: 70% of IWHS women reported taking aspirin compared to 46% in the NHS cohort (13); the percentage of those who regularly used aspirin (more than 2 times per week) was 38% in IWHS (1992), 21% in NHS (1990), and 11% in NHS-2 (1989) (19). IWHS women were older (age range at the start of follow-up was 58–76 years in IWHS versus 30–55 years in NHS and 25–42 years in NHS-II). Thus, the IWHS cohort, compared to NHS-NHS-II cohort is comprised of older women at risk for ovarian cancer who reported higher use of aspirin.

Our finding of an inverse association between aspirin use and incident ovarian cancer are consistent with positive associations between risk of ovarian cancer and increased CRP – a non-specific marker of inflammation (7), and an inverse association between aspirin treatment and human ovarian cancer cell growth in in vitro studies. The mechanism of an association between aspirin and ovarian cancer may be an anti-inflammatory effect of aspirin through inhibition of COX-1 and COX-2 (9). Laboratory studies showed that COX-2 is expressed in human ovarian carcinoma cell lines and high expression of COX-2 leads to an increased production of prostaglandin E2 resulting in poor patient prognosis (8). Aspirin was reported to inhibit the growth of human ovarian tumor cells in a dose-dependent fashion (9). It is possible that aspirin also exerts its inhibitory effect through COX-independent mechanism such as modulation of estrogen synthesis, the role of aspirin as an antioxidant, or some other mechanisms (8, 10, 39, 41), all of which may result in inhibition of angiogenesis, induction of apoptosis, and inhibition of oxidative DNA damage (42, 43).

We did not observe any dose-dependent relationship between frequency of non-aspirin NSAIDs use and ovarian cancer risk. This is compatible with the results of a meta-analysis by Bonovas et al (36). The reason for different results between aspirin and non-aspirin NSAIDs in our cohort may be that the protective effect on ovarian cancer may be limited to aspirin and reflects differences in mechanisms between aspirin and non-aspirin NSAIDs. For example, non-aspirin NSAIDs reversibly inactivate COX, whereas aspirin inactivates COX irreversibly. Moreover, non-aspirin NSAIDs are a heterogeneous group of medications, each with slightly different properties – various half-lives and effects on COX inhibition, and may have different effect on cancer risk (36). In addition, use of non-aspirin NSAID use in our cohort was assessed in 1992, when most non-aspirin NSAIDs medications were not available over-the counter and women may not have been very familiar with them and either recalled them poorly or took them only for a short time.

Our study has the following limitations: information about duration, dosage, and reason for NSAIDs use was not collected. We also had a concern about confounding by indication. For instance, women with heart disease could have taken aspirin because they had low-grade inflammation which could be associated with ovarian cancer. To minimize potential confounding by indication, we examined women without heart disease and found an inverse statistically significant association similar to that in the main analysis. The inverse relationships also held among those without history of migraines or arthritis. Another limitation is that exposure was assessed by self-report; therefore, some misclassification undoubtedly occurred. In cohort studies, misclassification of exposure is usually not associated with the outcome, is non-differential and most likely biases toward the null. However, because of potential residual confounding by indication, differential misclassification may be present; for example, women with heart disease or arthritis might recall their exposure history better than women without. Moreover, in rare cases, non-differential misclassification of a multi-level exposure may result in bias away from null (44, 45).

Furthermore, the questions about NSAIDs were asked only once at the start of follow-up, and the exposure could have changed over time. However, after stratification by the time of follow up at the midpoint, the inverse relationships between aspirin use and ovarian cancer risk were similar in both subgroups. Finally, we did not have power to examine ovarian cancer by histological subtype. The strengths of our study are that the IWHS is a large population-based prospective cohort with practically complete follow-up, reliable ascertainment of cancer cases, and detailed information about cancer risk factors. Moreover, we were able to separately examine frequency of aspirin and non-aspirin NSAIDs use.

Our findings support the hypothesis that aspirin use is inversely associated with ovarian cancer risk, but it has no effect on endometrial cancer risk. Large cohort studies or clinical trials with accurate assessment of dosage and duration of NSAIDs and information about age at the initiation of treatment are needed.

Acknowledgments

This study was supported by National Cancer Institute grant R01 CA39742. The authors are thankful to the IWHS staff for consultation and assistance in data preparation.

Footnotes

The author(s) indicated no potential conflicts of interest.

References

1. Balkwill F, Mantovani A. Inflammation and cancer: Back to Virchow? Lancet. 2001;357:539–45. [PubMed]
2. Schottenfeld D, Beebe-Dimmer J. Chronic inflammation: A common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin. 2006;56:69–83. [PubMed]
3. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–7. [PMC free article] [PubMed]
4. Modugno F, Ness RB, Chen C, Weiss NS. Inflammation and endometrial cancer: a hypothesis. Cancer Epidemiol Biomarkers Prev. 2005;14:2840–7. [PubMed]
5. Hankinson SE, Danforth KN. Ovarian cancer. In: Schottenfeld D, Fraumeni JF jr, editors. Cancer Epidemiology and Prevention. 3. New York: Oxford University Press; 2006. pp. 1013–26.
6. Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst. 1999;91:1459–67. [PubMed]
7. McSorley MA, Alberg AJ, Allen DS, et al. C-reactive protein concentrations and subsequent ovarian cancer risk. Obstet Gynecol. 2007;109:933–41. [PubMed]
8. Denkert C, Furstenberg A, Daniel PT, et al. Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference. Oncogene. 2003;22:8653–61. [PubMed]
9. Drake JG, Becker JL. Aspirin-induced inhibition of ovarian tumor cell growth. Obstet Gynecol. 2002;100:677–82. [PubMed]
10. Rodriguez-Burford C, Barnes MN, Oelschlager DK, et al. Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: Preclinical evaluation of NSAIDs as chemopreventive agents. Clin Cancer Res. 2002;8:202–9. [PubMed]
11. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Kato I, Koenig KL, Shore RE. Aspirin and epithelial ovarian cancer. Prev Med. 2001;33:682–7. [PubMed]
12. Cramer DW, Harlow BL, Titus-Ernstoff L, Bohlke K, Welch WR, Greenberg ER. Over-the-counter analgesics and risk of ovarian cancer. Lancet. 1998;351:104–7. [PubMed]
13. Fairfield KM, Hunter DJ, Fuchs CS, Colditz GA, Hankinson SE. Aspirin, other NSAIDs, and ovarian cancer risk (United States) Cancer Causes Control. 2002;13:535–42. [PubMed]
14. Hannibal CG, Rossing MA, Wicklund KG, Cushing-Haugen KL. Analgesic drug use and risk of epithelial ovarian cancer. Am J Epidemiol. 2008;167:1430–7. [PubMed]
15. Lacey JV, Jr, Sherman ME, Hartge P, Schatzkin A, Schairer C. Medication use and risk of ovarian carcinoma: a prospective study. Int J Cancer. 2004;108:281–6. [PubMed]
16. Meier CR, Schmitz S, Jick H. Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer. Pharmacotherapy. 2002;22:303–9. [PubMed]
17. Merritt MA, Green AC, Nagle CM, Webb PM. Australian Cancer Study (Ovarian Cancer), Australian Ovarian Cancer Study Group. Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer. 2008;122:170–6. [PubMed]
18. Moysich KB, Mettlin C, Piver MS, Natarajan N, Menezes RJ, Swede H. Regular use of analgesic drugs and ovarian cancer risk. Cancer Epidemiol Biomarkers Prev. 2001;10:903–6. [PubMed]
19. Pinheiro SP, Tworoger SS, Cramer DW, Rosner BA, Hankinson SE. Use of nonsteroidal antiinflammatory agents and incidence of ovarian cancer in 2 large prospective cohorts. Am J Epidemiol. 2009;169:1378–87. [PMC free article] [PubMed]
20. Rosenberg L, Palmer JR, Rao RS, et al. A case-control study of analgesic use and ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2000;9:933–7. [PubMed]
21. Schildkraut JM, Moorman PG, Halabi S, Calingaert B, Marks JR, Berchuck A. Analgesic drug use and risk of ovarian cancer. Epidemiology. 2006;17:104–7. [PubMed]
22. Sorensen HT, Friis S, Norgard B, et al. Risk of cancer in a large cohort of nonaspirin NSAID users: A population-based study. Br J Cancer. 2003;88:1687–92. [PMC free article] [PubMed]
23. Tavani A, Gallus S, La Vecchia C, Conti E, Montella M, Franceschi S. Aspirin and ovarian cancer: An Italian case-control study. Ann Oncol. 2000;11:1171–3. [PubMed]
24. Tzonou A, Polychronopoulou A, Hsieh CC, Rebelakos A, Karakatsani A, Trichopoulos D. Hair dyes, analgesics, tranquilizers and perineal talc application as risk factors for ovarian cancer. Int J Cancer. 1993;55:408–10. [PubMed]
25. Wernli KJ, Newcomb PA, Hampton JM, Trentham-Dietz A, Egan KM. Inverse association of NSAID use and ovarian cancer in relation to oral contraceptive use and parity. Br J Cancer. 2008;98:1781–3. [PMC free article] [PubMed]
26. Arango HA, Icely S, Roberts WS, Cavanagh D, Becker JL. Aspirin effects on endometrial cancer cell growth. Obstet Gynecol. 2001;97:423–7. [PubMed]
27. Gao J, Niwa K, Sun W, et al. Non-steroidal anti-inflammatory drugs inhibit cellular proliferation and upregulate cyclooxygenase-2 protein expression in endometrial cancer cells. Cancer Sci. 2004;95:901–7. [PubMed]
28. Li HL, Zhang HW, Chen DD, Zhong L, Ren XD, St-Tu R. JTE-522, a selective COX-2 inhibitor, inhibits cell proliferation and induces apoptosis in RL95-2 cells. Acta Pharmacol Sin. 2002;23:631–7. [PubMed]
29. Danforth KN, Gierach GL, Brinton LA, et al. Nonsteroidal anti-inflammatory drug use and endometrial cancer risk in the NIH-AARP Diet and Health Study. Cancer Prev Res. 2009;2:466–72. [PMC free article] [PubMed]
30. Moysich KB, Baker JA, Rodabaugh KJ, Villella JA. Regular analgesic use and risk of endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:2923–8. [PubMed]
31. Viswanathan AN, Feskanich D, Schernhammer ES, Hankinson SE. Aspirin, NSAID, and acetaminophen use and the risk of endometrial cancer. Cancer Res. 2008;68:2507–13. [PMC free article] [PubMed]
32. Bisgard KM, Folsom AR, Hong CP, Sellers TA. Mortality and cancer rates in nonrespondents to a prospective study of older women: 5-year follow-up. Am J Epidemiol. 1994;139:990–1000. [PubMed]
33. Folsom AR, Kaye SA, Prineas RJ, Potter JD, Gapstur SM, Wallace RB. Increased incidence of carcinoma of the breast associated with abdominal adiposity in postmenopausal women. Am J Epidemiol. 1990;131:794–803. [PubMed]
34. Folsom AR, Kushi LH, Anderson KE, et al. Associations of general and abdominal obesity with multiple health outcomes in older women: The Iowa Women’s Health Study. Arch Intern Med. 2000;160:2117–28. [PubMed]
35. Zhang S, Folsom AR, Sellers TA, Kushi LH, Potter JD. Better breast cancer survival for postmenopausal women who are less overweight and eat less fat. The Iowa Women’s Health Study. Cancer. 1995;76:275–83. [PubMed]
36. Bonovas S, Filioussi K, Sitaras NM. Do nonsteroidal anti-inflammatory drugs affect the risk of developing ovarian cancer? A meta-analysis. Br J Clin Pharmacol. 2005;60:194–203. [PubMed]
37. Bosetti C, Gallus S, La Vecchia C. Aspirin and cancer risk: An updated quantitative review to 2005. Cancer Causes Control. 2006;17:871–88. [PubMed]
38. Gonzalez-Perez A, Garcia Rodriguez LA, Lopez-Ridaura R. Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer. 2003;3:28. [PMC free article] [PubMed]
39. Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: The Women’s Health Study: A randomized controlled trial. JAMA. 2005;294:47–55. [PubMed]
40. Mahipal A, Anderson KE, Limburg PJ, Folsom AR. Nonsteroidal anti-inflammatory drugs and subsite-specific colorectal cancer incidence in the Iowa Women’s Health Study. Cancer Epidemiol Biomarkers Prev. 2006;15:1785–90. [PubMed]
41. Cuzick J, Otto F, Baron JA, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: An international consensus statement. Lancet Oncol. 2009;10:501–7. [PubMed]
42. Hsu CS, Li Y. Aspirin potently inhibits oxidative DNA strand breaks: Implications for cancer chemoprevention. Biochem Biophys Res Commun. 2002;293:705–9. [PubMed]
43. Husain SS, Szabo IL, Tamawski AS. NSAID inhibition of GI cancer growth: Clinical implications and molecular mechanisms of action. Am J Gastroenterol. 2002;97:542–53. [PubMed]
44. Dosemeci M, Wacholder S, Lubin JH. Does nondifferential misclassification of exposure always bias a true effect toward the null value? Am J Epidemiol. 1990;132:746–8. [PubMed]
45. Blair A, Stewart P, Lubin JH, Forastiere F. Methodological issues regarding confounding and exposure misclassification in epidemiological studies of occupational exposures. Am J Ind Med. 2007;50:199–207. [PubMed]